Novo Nordisk downgrade seen as overdone
The panel disagreed with Deutsche Bank's downgrade of Novo Nordisk, arguing the stock is cheap and the bear case overlooks the strength of its broader business beyond GLP-1 drugs.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.